2024-05-09 08:15:00 ET
Summary
- Teva Pharmaceutical stock has been trending higher since October 2023, closing at nearly $16.00.
- The company reported strong first-quarter results, with increased revenue and growth in key metrics.
- Teva has a positive business outlook for 2024, with a forecast for adjusted EBITDA of up to $5.0 billion and potential blockbuster drugs in its pipeline.
Since October 2023, shares of Teva Pharmaceutical ( TEVA ) trended higher from around $8.00 to close at $15.74. In addition to earning a bullish “Buy” quant rating in early April, what are the fundamentals that changed following Teva’s first-quarter results?...
Read the full article on Seeking Alpha
For further details see:
Teva Pharmaceutical: 6 Takeaways From Q1 2024 Earnings Results